Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 136 to 150 of 166 results for low back pain

  1. Ustekinumab for the treatment of adults with moderate to severe psoriasis (TA180)

    Evidence-based recommendations on ustekinumab (Stelara) for treating psoriasis in adults.

  2. Appeal panel membership

    Society and the international non-governmental organisation Teaching-aids at Low Cost (TALC). He has been a lay member of the NICE...

  3. Managing medicines for adults receiving social care in the community (NG67)

    This guideline covers medicines support for adults (aged 18 and over) who are receiving social care in the community. It aims to ensure that people who receive social care are supported to take and look after their medicines effectively and safely at home. It gives advice on assessing if people need help with managing their medicines, who should provide medicines support and how health and social care staff should work together.

  4. Supporting adult carers (NG150)

    This guideline covers support for adults (aged 18 and over) who provide unpaid care for anyone aged 16 or over with health or social care needs. It aims to improve the lives of carers by helping health and social care practitioners identify people who are caring for someone and give them the right information and support. It covers carers’ assessments, practical, emotional and social support and training, and support for carers providing end of life care.

  5. Galcanezumab for preventing migraine (TA659)

    Evidence-based recommendations on galcanezumab (Emgality) for preventing migraine in adults.

  6. Relugolix–estradiol–norethisterone acetate for treating moderate to severe symptoms of uterine fibroids (TA832)

    Evidence-based recommendations on relugolix–estradiol–norethisterone acetate (Ryeqo) for treating moderate to severe symptoms of uterine fibroids in adults of reproductive age.

  7. Minimally invasive percutaneous nephrolitholapaxy medium (MIP-M) for removing kidney stones (MIB138)

    NICE has developed a medtech innovation briefing (MIB) on minimally invasive percutaneous nephrolitholapaxy medium (MIP-M) for removing kidney stones .

  8. Peptest for diagnosing gastro‑oesophageal reflux (MIB31)

    NICE has developed a medtech innovation briefing (MIB) on Peptest for diagnosing gastro-oesophageal reflux

  9. TopClosure Tension Relief System for wound closure (MIB97)

    NICE has developed a medtech innovation briefing (MIB) on TopClosure Tension Relief System for wound closure .

  10. Dapagliflozin in triple therapy for treating type 2 diabetes (TA418)

    Evidence-based recommendations on dapagliflozin (Forxiga) given with 2 other drugs for treating type 2 diabetes in adults.

  11. Dapagliflozin in combination therapy for treating type 2 diabetes (TA288)

    Evidence-based recommendations on dapagliflozin (Forxiga) given with other drugs for treating type 2 diabetes in adults.

  12. ATEC system for vacuum-assisted breast biopsy (MIB43)

    NICE has developed a medtech innovation briefing (MIB) on the ATEC breast biopsy system

  13. Remote ECG interpretation consultancy services for cardiovascular disease (MIB152)

    NICE has developed a medtech innovation briefing (MIB) on remote ECG interpretation consultancy services for cardiovascular disease .

  14. Tobacco: preventing uptake, promoting quitting and treating dependence (NG209)

    This guideline covers support to stop smoking for everyone aged 12 and over, and help to reduce people's harm from smoking if they are not ready to stop in one go . It also covers ways to prevent children, young people and young adults aged 24 and under from taking up smoking. The guideline brings together and updates all NICE's previous guidelines on using tobacco, including smokeless tobacco . It covers nicotine replacement therapy and e-cigarettes to help people stop smoking or reduce their harm from smoking. It does not cover using tobacco products such as ‘heat not burn’ tobacco.

  15. Ustekinumab for treating active psoriatic arthritis (TA340)

    Evidence-based recommendations on ustekinumab (Stelara) for treating active psoriatic arthritis in adults.